Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Feb 16;13(2):376-382.
doi: 10.1021/acschembio.7b00680. Epub 2017 Oct 19.

The Promise and Challenge of In Vivo Delivery for Genome Therapeutics

Ross C Wilson  1   2 , Luke A Gilbert  1   3   4
Affiliations
Review

The Promise and Challenge of In Vivo Delivery for Genome Therapeutics

Ross C Wilson et al. ACS Chem Biol. .

Abstract

CRISPR-based genome editing technologies are poised to enable countless new therapies to prevent, treat, or cure diseases with a genetic basis. However, the safe and effective delivery of genome editing enzymes represents a substantial challenge that must be tackled to enable the next generation of genetic therapies. In this Review, we summarize recent progress in developing enzymatic tools to combat genetic disease and examine current efforts to deliver these enzymes to the cells in need of correction. Viral vectors already in use for traditional gene therapy are being applied to enable in vivo CRISPR-based therapeutics, as are emerging technologies such as nanoparticle-based delivery of CRISPR components and direct delivery of preassembled RNA-protein complexes. Success in these areas will allow CRISPR-based genome editing therapeutics to reach their full potential.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Three strategies for in vivo genome-editing enzyme delivery and their key properties.
See this image and copyright information in PMC

References

    1. Yi L, Li J. CRISPR-Cas9 therapeutics in cancer: promising strategies and present challenges. Bioch Biophys Acta. 2016;1866:197–207. - PubMed
    1. Li X, Wu R, Ventura A. The present and future of genome editing in cancer research. Hum Genet. 2016;135:1083–92. - PMC - PubMed
    1. Ren J, Zhao Y. Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9. Protein Cell. 2017;8:634–643. - PMC - PubMed
    1. Ely A, Moyo B, Arbuthnot P. Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus. Mol Ther. 2016;24:671–677. - PMC - PubMed
    1. Deleidi M, Yu C. Genome editing in pluripotent stem cells: research and therapeutic applications. Biochem Biophys Res Commun. 2016;473:665–74. - PubMed

Publication types

Substances